コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 (26/50) revealed a classical fully synapsed quadrivalent.
2 with the X-Y bivalent to form trivalents and quadrivalents.
6 ination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vac
9 papillomas and has been included in both the quadrivalent and nonavalent prophylactic HPV vaccines.
10 ures of clade C Env trimers and found that a quadrivalent cocktail of clade C trimers elicited a grea
13 uch as immunoglobulin G (IgG) because of its quadrivalent domains that bind to the Fc region of these
14 onal influenza vaccines are transitioning to quadrivalent formulations including the hemagglutinins o
15 We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B
17 omavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and
18 and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine.
19 lected for the efficacy determination of the quadrivalent HPV (type 6, 11, 16, and 18) L1 virus-like
20 lected for the efficacy determination of the quadrivalent HPV (type 6, 11, 16, and 18) L1 virus-like
21 assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HI
22 hronic oral papillomas with resolution after quadrivalent HPV vaccination and perform a review of the
23 sed by HPV-32 with complete resolution after quadrivalent HPV vaccination and reviewed reports of res
25 omized clinical trials to assess efficacy of quadrivalent HPV vaccination for treatment of oral squam
27 here were 4127 female patients who initiated quadrivalent HPV vaccination or had their first missed H
31 ars who had previously completed a series of quadrivalent HPV vaccine (4vHPV), a strategy we refer to
32 ly vaccinated with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 year
37 s) were randomized 1:1 to receive 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261)
41 o determine immunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening
43 12,343 subjects 9-26 years old randomized to quadrivalent HPV vaccine or placebo in phase 2/3 studies
45 mary efficacy objective was to show that the quadrivalent HPV vaccine reduced the incidence of extern
48 antly more frequent among subjects receiving quadrivalent HPV vaccine than among those receiving plac
49 aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this ana
50 r age groups revealed that the prevalence of quadrivalent HPV vaccine types (4vHPV), types 6, 11, 16,
54 has condyloma or HPV-6/11 infection with the quadrivalent HPV vaccine will result in a high neutraliz
55 ma risk was seen after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was
60 targeted by currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and
61 aged 16-26 years were randomised to receive quadrivalent HPV6/11/16/18 vaccine (n=9087), its HPV16 v
63 who were enrolled in the phase 3 trials of a quadrivalent human papillomavirus (HPV) 6/11/16/18 vacci
66 d by 2 different delivery strategies for the quadrivalent human papillomavirus (HPV) vaccine in Tanza
69 is study was to determine whether the 3-dose quadrivalent human papillomavirus (HPV) vaccine series (
74 he Food and Drug Administration licensed the quadrivalent human papillomavirus (types 6, 11, 16, and
75 itu hybridization (FISH) analysis of meiotic quadrivalents in 16 single and 2 double translocation he
77 determined the effectiveness of trivalent or quadrivalent inactivated influenza vaccine (IIV) among s
78 cine (RIV4) with a standard-dose, egg-grown, quadrivalent, inactivated influenza vaccine (IIV4) durin
79 ed directly with a standard-dose, egg-grown, quadrivalent-inactivated influenza vaccine (IIV4) for im
80 ated the efficacy of a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B l
82 immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate (QIV) versus tr
83 comparison of recombinant versus inactivated quadrivalent influenza vaccines in 18-49 year old adults
84 t a surprising natural design to achieve the quadrivalent inhibition of translation through a highly
85 ts ages >/=6 months and the effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) a
88 n Practices now recommends immunization with quadrivalent meningococcal conjugate vaccine for all pre
89 live attenuated influenza virus vaccine and quadrivalent meningococcal conjugate vaccine for use in
90 e vaccination of HIV-infected persons with a quadrivalent meningococcal conjugate vaccine in accordan
91 Students at participating schools received quadrivalent meningococcal conjugate vaccine that uses d
94 influenza vaccine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37;
95 events were reported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) wom
96 d influenza were first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the
97 group and 1793 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed u
98 njection site was more common in women given quadrivalent meningococcal vaccine than in those given t
100 Unlike that for serogroups prevented by quadrivalent meningococcal vaccines, public health respo
101 c segregation distortion, mixed bivalent and quadrivalent pairing in meiosis, and incomplete informat
102 year after vaccination with either PsA-TT or quadrivalent polysaccharide vaccine (PsACWY) from a rand
107 the protective efficacy in older adults of a quadrivalent, recombinant influenza vaccine (RIV4) with
108 t (HZ/su) vaccine when coadministered with a quadrivalent seasonal inactivated influenza vaccine (IIV
111 n 2014, prevents 4 HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-
113 who received dose 1 (pupil controls) of the quadrivalent vaccine (Gardasil) and their parents/guardi
114 the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6, -11, -16, and -18) will be
115 timate the cost-effectiveness of HPV9 versus quadrivalent vaccine (HPV4), assuming lifelong vaccine p
116 PV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measura
118 Four VP7 serotypes were incorporated into a quadrivalent vaccine comprised of three rhesus-human rot
119 alent vaccine containing HPV 16 and 18 and a quadrivalent vaccine containing HPV 6, 11, 16, and 18 an
120 antigens were delivered simultaneously as a quadrivalent vaccine in order to compensate for this var
121 d immunogenicity of the human papillomavirus quadrivalent vaccine in people with HIV have started enr
122 nical trial of rhesus monkey rotavirus-based quadrivalent vaccine in Venezuela, 2207 infants received
123 uestions about the added benefits of using a quadrivalent vaccine instead of a trivalent vaccine.
124 iew summarizes the guidelines for use of the quadrivalent vaccine published by the Advisory Committee
129 PV types 6, 11, 16, and 18 (HPV types in the quadrivalent vaccine) among 4303 persons aged 14-59 year
130 ed States of all 4 HPV types targeted by the quadrivalent vaccine, and its findings can inform vaccin
131 roduction system that is also used for their quadrivalent vaccine, is the first second-generation HPV
132 t respiratory papillomatosis by means of the quadrivalent vaccine, the duration of immunity, and futu
135 ost-effective compared with the bivalent and quadrivalent vaccines at any coverage despite the greate
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。